Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study

• DOI: 10.1164/rccm.201512-2523oc
• Publication Date: 2016-06-17T19:40:52Z
• Authors: Tetsuro Araki; Rachel K. Putman; Hiroto Hatabu; Wei Gao; Josée Dupuis; Jeanne C. Latourelle; Mizuki Nishino; Oscar E. Zazueta; Sila Kurugol; James C. Ross; Raúl San José Est...; David A. Schwartz; Ivan O. Rosas; George R. Washko; George T. O’Connor; Gary M. Hunninghake
• Keywords: Framingham Heart Study

The relationship between the development and/or progression of interstitial lung abnormalities (ILA) and clinical outcomes has not been previously investigated.To determine risk factors for, consequences of, having ILA in participants from Framingham Heart Study.ILA were assessed 1,867 who had serial chest computed tomography (CT) scans approximately 6 years apart. Mixed effect regression (and Cox) models used to assess association pulmonary function decline mortality).During follow-up period 660 (35%) did have on either CT scan, 37 (2%) stable improving ILA, 118 (6%) with (the remaining without noted be indeterminate at least one scan). Increasing age increasing copies MUC5B promoter polymorphism associated progression. After adjustment for covariates, was a greater FVC when compared (20 ml; SE, ±6 P = 0.0005) those (25 ±11 0.03). Over median time 4 years, after adjustment, an increase death (hazard ratio, 3.9; 95% confidence interval, 1.3-10.9; 0.01) ILA.These findings demonstrate that Study is increased rate death.